Trials / Terminated
TerminatedNCT01602120
An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab (FCFD4514S) in Patients With Geographic Atrophy Who Have Completed Genentech-Sponsored Lampalizumab Studies
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 159 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 60 Years – 89 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label extension study of safety and tolerability of lampalizumab administered by intravitreal (ITV) injection to participants with geographic atrophy (GA) who have completed the 18-month treatment in Study CFD4870g (GX01456) (NCT01229215) or 24-week treatment in Study GX29455 (NCT02288559).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lampalizumab | Lampalizumab 10 mg ITV injections as per the schedule specified in respective arms. |
Timeline
- Start date
- 2012-05-29
- Primary completion
- 2017-11-08
- Completion
- 2018-02-09
- First posted
- 2012-05-18
- Last updated
- 2019-09-11
- Results posted
- 2019-02-21
Locations
46 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT01602120. Inclusion in this directory is not an endorsement.